查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2022530

普拉德-威利症候群（PWS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Prader-Willi Syndrome (PWS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 155 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

普拉德-威利症候群（PWS）概述

Prader-Willi 症候群 (PWS) 是一種罕見的、複雜的、多系統疾病，由位於 15 號染色體 q11.2–q13 區域的父系遺傳印記基因表達缺失引起。這種基因缺失主要由父系缺失或母系單基因二倍體引起，導致嚴重的下視丘功能障礙，這是此疾病表現型的核心因素。

臨床上，普拉德-威利症候群（PWS）的病程呈現明顯的雙相性。新生兒期，其特徵為嚴重的中樞性肌張力低下、飲食障礙和發育不良。到了嬰兒早期，病情會發展為病理性過度餵養，表現為飽腹感訊號受損和持續不斷的進食行為。若不進行積極干預，可導致迅速的肥胖和繼發性代謝併發症，包括第2型糖尿病和嚴重的阻塞型睡眠呼吸中止症呼吸中止症候群。

除了代謝負擔外，普拉德-威利症候群（PWS）還伴隨多種神經行為和內分泌症狀，包括輕度至中度智慧障礙、強迫症、情緒失調、性腺功能減退和中樞性生長激素缺乏。此病的治療仍需大量資源和多學科協作。早期啟動重組人體生長荷爾蒙（rhGH）治療是治療的關鍵，可改善身高成長、身體組成和代謝指標。然而，目前尚無核准的治療方法過度進食的方法，仍是此病最亟待解決的問題。因此，長期疾病管理主要依賴嚴格的環境措施（例如飲食限制）和持續的看護者監督。

主要亮點：

  • PWS 是一種罕見的、終身性的多系統疾病，由下視丘功能障礙引起。雖然美國確診患者的數量保持穩定，但正在逐漸增加。
  • 由於診斷技術的進步和生存時間的延長，預計美國患有該疾病的人數將從 2025 年的 13,900 人增加到 2035 年的 14,800 人，呈現漸進成長的趨勢（年複合成長率為 0.6%–0.7%）。
  • 這種疾病的特徵是嚴重的過度進食和肥胖相關併發症，由於缺乏核准的標靶治療，因此成為最重要的未滿足需求。
  • 鑑於臨床上對以食慾調節和下視丘路徑為標靶的治療方法的關注度日益提高，未來的治療模式預計將發生重大變化。

市場概況：

  • 美國普瑞德威利症候群 (PWS) 市場預計將從 2025 年的 5.59 億美元成長到 2035 年的 39.6 億美元，反映出強勁的兩位數複合年成長率，這主要得益於針對神經性貪食症的後期開發療法的推動。
  • 目前市場收入主要由重組人體生長荷爾蒙(rhGH) 療法驅動，該療法可解決生長和代謝問題，但無法解決貪食症。
  • 未來市場擴張將很大程度上取決於針對食慾失調和改善長期疾病結果的治療方法的商業化成功。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Harmony Biosciences Management, Inc.
  • ConSynance Therapeutics
  • Soleno Therapeutics, Inc.
  • Bright Minds Biosciences Pty Ltd
  • Aardvark Therapeutics, Inc.
  • Pfizer
  • Rhythm Pharmaceuticals, Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興治療方法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Prader-Willi Syndrome (PWS) Market Outlook

Thelansis's "Prader-Willi Syndrome (PWS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prader-Willi Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Prader-Willi Syndrome (PWS) Overview

Prader-Willi Syndrome (PWS) is a rare, complex, multisystem disorder driven by loss of expression of paternally inherited imprinted genes on chromosome 15q11.2-q13. This genetic defect most commonly arises from a paternal deletion or maternal uniparental disomy, leading to profound hypothalamic dysfunction-the central driver of the disease phenotype.

Clinically, PWS follows a well-defined biphasic trajectory. The neonatal phase is marked by severe central hypotonia, poor feeding, and failure to thrive. This transitions in early childhood to pathologic hyperphagia, characterized by impaired satiety signaling and relentless food-seeking behavior. Without strict intervention, this results in rapid-onset obesity and downstream metabolic complications, including Type 2 Diabetes and severe Obstructive Sleep Apnea.

Beyond metabolic burden, PWS presents with a broad neurobehavioral and endocrine spectrum, including mild-to-moderate intellectual disability, compulsive behaviors, emotional dysregulation, hypogonadism, and central growth hormone deficiency. Management remains highly resource-intensive and multidisciplinary. Early initiation of recombinant human growth hormone (rhGH) therapy is the cornerstone of care, demonstrating benefits in linear growth, body composition, and metabolic parameters. However, there are no approved therapies targeting hyperphagia, which remains the most critical unmet need. As a result, long-term disease control depends heavily on stringent environmental measures (e.g., food security restrictions) and continuous caregiver supervision.

Key Highlights:

  • PWS is a rare, lifelong, multisystem disorder driven by hypothalamic dysfunction, with a stable but gradually increasing diagnosed patient population in the US.
  • The US prevalent population is estimated to grow from 13.9K in 2025 to 14.8K by 2035, reflecting a modest growth trajectory (0.6-0.7% CAGR) driven by improved diagnosis and survival.
  • The disease is characterized by severe hyperphagia and obesity-related complications, representing the most critical unmet need due to the absence of approved targeted therapies.
  • Increasing clinical focus on appetite-regulating and hypothalamic pathway-targeted therapies is expected to significantly transform the future treatment landscape.

Market Overview:

  • The US PWS market is projected to expand from $559M in 2025 to $3.96B by 2035, reflecting a strong double-digit CAGR, primarily driven by late-stage pipeline therapies targeting hyperphagia.
  • Current market revenues are largely supported by recombinant human growth hormone (rhGH) therapy, which addresses growth and metabolic aspects but not hyperphagia.
  • Future market expansion will be highly dependent on successful commercialization of therapies targeting appetite dysregulation and improving long-term disease outcomes.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Harmony Biosciences Management, Inc.
  • ConSynance Therapeutics
  • Soleno Therapeutics, Inc.
  • Bright Minds Biosciences Pty Ltd
  • Aardvark Therapeutics, Inc.
  • Pfizer
  • Rhythm Pharmaceuticals, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)